The SNM practice guideline for somatostatin receptor scintigraphy 2.0

Journal of Nuclear Medicine Technology

Volumn 39, Issue 4, 2011, Pages 317-324

  Balon, Helena R ^a   Brown, Tracy L Y ^b   Goldsmith, Stanley J ^c   Silberstein, Edward B ^d   Krenning, Eric P ^e   Lang, Otto ^f   Dillehay, Gary ^g   Tarrance, Jennifer C N M T ^a   Johnson, Matt C N M T ^a   Stabin, Michael G ^h  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CHARLES UNIVERSITY   (Czech Republic)

^g NORTHWESTERN UNIVERSITY   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; BLEOMYCIN; GALLIUM EDETATE GA 68; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ADRENAL TUMOR; ARTICLE; ASTROCYTOMA; BONE TUMOR; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CARCINOID; COLLIMATOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PURITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HYPOPHYSIS ADENOMA; IMAGE PROCESSING; INFECTION CONTROL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MEDICAL DOCUMENTATION; MEDICAL HISTORY; MEDICAL SOCIETY; MELANOMA; MENINGIOMA; MERKEL CELL TUMOR; METASTASIS; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT SAFETY; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; QUALITY CONTROL; RADIATION SAFETY; SARCOMA; SCINTIGRAPHY; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; THREE DIMENSIONAL IMAGING; TOTAL PARENTERAL NUTRITION; TUMOR LOCALIZATION;

HUMANS; NEUROENDOCRINE TUMORS; NUCLEAR MEDICINE; PRACTICE GUIDELINES AS TOPIC; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; UNITED STATES;

EID: 84863393518     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.111.098277     Document Type: Article

References (41)

1. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441-1448.
2. Gibril F, Reynolds JC, Chen CC, et al. Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in-patients with gastrinomas. J Nucl Med. 1999;40:539-553.
3. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med. 1996;125:26-34.
4. 111indium pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542-549.
5. Reisinger I, Bohuslavitzki KH, Brenner W, et al. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med. 1998;39:224-227.
6. Schmidt M, Scheidhauer K, Luyken C, et al. Somatostatin receptor imaging in intracranial tumours. Eur J Nucl Med. 1998;25:675-686.
7. Goldsmith SJ. Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol. 2009;5:75-84.
8. Timmers HJLM, Chen CC, Carasquillo JA, et al. Comparison of F-18-fluoro-LDOPA, F-18-fluoro-deoxyglucose, and F-18-fluorodopamine PET and I-123 MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-4767.
9. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [In-111-DTPA-d-Phe1] and [I-123-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
10. 111In-pentetreotide in medulloblastoma: a comparison with magnetic resonance imaging. Acta Oncol. 2007;46: 111-117.
11. Duet M, Sauvaget E, Petelle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767-1774.
12. 111In-pentetreotide. Neuroendocrinology. 2009;90:184-189.
13. 111In-octreotide imaging in staging of small cell lung cancer. Clin Nucl Med. 1997;22:811-816.
14. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853-858.
15. OctreoScan [package insert]. Loma Linda, CA: Mallinckrodt Medical Inc.; October 2006.
16. 111indium pentetreotide (OctreoScan). Semin Nucl Med. 1995;25:251-261.
17. National Comprehensive Cancer Network Web site. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: neuroendocrine tumors, version 1.2011 [available at: http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed October 17, 2011], and small cell lung cancer, version 2.2012 [available at: http://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed October 17, 2011].
18. Khanna G, Bushnell D, O'Dorisio MS. Utility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptorpositive pediatric tumors. Oncologist. 2008;13:382-389.
19. Klutmann S, Bohuslavizki KH, Brenner W, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med. 1998;39:1913-1917.
20. Khanna G, O'Dorisio MS, Menda Y, et al. Somatostatin receptor scintigraphy in surveillance of pediatric brain malignancies. Pediatr Blood Cancer. 2008; 50:561-566.
21. O'Dorisio MS, Kanna G, Bushnell D. Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children. Cancer Metastasis Rev. 2008;27:665-677.
22. van Essen M, Krenning EP, Kam BLR, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
23. Cavalla P, Schiffer D. Neuroendocrine tumors in the brain. Ann Oncol. 2001;12(suppl 2):S131-S134.
24. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of therapy with high-activity 111In-pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008;23:292-300.
25. Kwekkeboom DJ, Krenning EP, Kho GS, et al. Somatostatin receptor imaging in patients with sarcoidosis. Eur J Nucl Med. 1998;25:1284-1292.
26. Kwekkeboom DJ, Krenning EP. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Eur Radiol. 1997;7:1103-1109.
27. 111In-octreotide creates new clinical indications in benign disease, but also in oncology. Q J Nucl Med Mol Imaging. 2010;54:24-36.
28. 111Inpentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol. 2010;17:291-297.
29. 111Inpentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59:565-573.
30. 111Indium octreotide SPECT/CT for neuroendocrine tumor imaging. In: Israel O, Goldsmith SJ, eds. Hybrid SPECT/CT Imaging in Clinical Practice. Philadelphia, PA: Taylor and Francis; 2006:77-92.
31. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228-247.
32. Torre JJ, Bloomgarden ZT, Dickey RA, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of hypertension. Endocr Pract. 2006;12:193-222.
33. Tenenbaum F, Lumbroso J, Schlumberger M, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med. 1995;36:1-6.
34. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:203-220.
35. 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007;81:167-174.
36. Gelfand MJ, Parisi M, Treves ST. Pediatric radiopharmaceutical administered doses: 2010 North American Consensus Guidelines. J Nucl Med. 2011;52:318-322.
37. International Commission on Radiological Protection. ICRP Publication 106: Radiation Dose to Patients from Radiopharmaceuticals-A Third Addendum to ICRP Publication 53. Philadelphia, PA: Elsevier; 2009.
38. 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50:858-864.
39. 111indium pentetreotide. Endocr Pract. 2009;15:521-527.
40. Gabriel M, Decristoforo C, Kendler D, et al. Ga-68 DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518.
41. Russell JR, Stabin MG, Sparks RB, Watson EE. Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. Health Phys. 1997;73:756-769.